Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Microsoft word - cv-fy2009-july 2009.doc


Name:

Varsha

Present Title and Affiliation:
Primary
Director of Education & Faculty Development Joint Appointment Department of Leukemia The University of Texas M. D. Anderson Cancer Center The University of Texas M. D. Anderson Cancer Center
Citizenship:
U.S.A.

Office Address:
Education:
Degree-Granting Education:
Kanpur University, Kanpur, India, B.Sc., 1971 (Biology, Chemistry, Physics) Kanpur University, Kanpur, India, M.Sc., 1973 (Botany) Delhi University, Delhi, India, Ph.D., 1981 (Biochemistry) Research Fellow, Supervisor C. B. Sehgal, Ph.D. Postdoctoral Fellow, Supervisor J. Procunier, Ph.D. Postdoctoral Fellow, Supervisor W. Plunkett, Ph.D.
Credentials:
Board Certification: N/A

Experience/Service:
Academic and Professional Appointments:
1987-1989
University of Texas M D Anderson Cancer Center University of Texas M D Anderson Cancer Center University of Texas M D Anderson Cancer Center University of Texas M D Anderson Cancer Center University of Texas M D Anderson Cancer Center Director of Education & Faculty Development, 2005-present UT M. D. Anderson Cancer Center, Houston, Texas Deputy Department Chair, Ad interim, 2003-2005 UT M. D. Anderson Cancer Center, Houston, Texas Member, Animal Care & Use Committee, 1993-1995 Member, Minority Faculty & Administr. Committee, 1993-present Department Representative, Faculty Senate, 1998-2005 Judge, Trainee Recognition Day, M. D. Anderson Associates, 1999 Member, Subcommittee, Faculty Peer & Grievance Review Committee, 1999 Member, Research Council Subcommittee Research Laboratory Space Committee (Dr. DiGiovanni -Chair), 1999 Member, Study Section Review Committee, Basic Research Projects Institutional Research Grants Program, 1999-2002 Member, Academic Standards Committee Graduate school of Biomedical Sciences, 1999-2002 Member, Research Council Subcommittee Research Laboratory Space Committee (Dr. Klein - Chair), 2000-2003 Department Representative, Appeals Panel Faculty Peer & Grievance Review, 2000-2004 Member, Executive Committee of Faculty Senate, 2000-2005 Chair, Organizing Committee Experimental Therapeutics Seminar Series, 2001-2007 Member, Conflict Management Advisory Committee, 2001-2005 Dept of Experimental Radiation Oncology, Reviewer, 2003 Seed Grants Coordinator, GSBS Course Mechanisms in Cancer Therapeutics, 2003-present Coordinator, GSBS Course Principles of Therapeutics, 2008-2009 Member, Conflict of Interest Committee, 2003-2007 Organizing Committee Experimental Therapeutics Newsletter, 2005-present Organizing Committee Experimental Therapeutics Website, 2005-present Organizing Committee Experimental Therapeutics Seminar Series, 2007-present Member, Organizing Committee Division of Cancer Medicine Grand Rounds, 2005-present Member, Curriculum Committee Graduate School of Biomedical Sciences, 2005-2008 Member, Odyssey Postdoctoral Program Review Committee, 2005-2008 Member, Postdoctoral Advisory Committee, 2006-2008 Chair Elect, 2006 - 2007 Chair, 2007 - 2008 Annual Performance Evaluation Process, 1999 Institutional Diversity Faculty Focus Group, 1998 Other Appointments/Responsibilities: None ArQule, Inc., Woburn, MA, Consultant for mechanism based combinations of nucleoside analogs with ARQ agents, 2004 – 2005 ILEX Oncology, Inc., San Antonio, TX, Consultant and participant for FDA-ODAC meeting for the approval of clofarabine for pediatric acute leukemias, 2004 - 2005 BioCryst Pharmaceuticals, Inc., Birmingham, AL, Consultant for pharmacodynamic endpoints of BCX-1777, forodesine, 2004 - 2008 Genzyme Oncology, Inc., San Antonio, TX, Consultant for post-approval development of clofarabine for pediatric acute leukemias, 2005 - 2007 Bioenvision Limited, Edinburgh, U.K. Consultant for clofarabine development in Europe, 2005 - 2007 GlaxoSmithKline, Inc., Collegeville, PA, Consultant and participant for FDA-ODAC meeting for the approval of nelarabine for T-cell pediatric and adult acute leukemias, 2005 Military or Other Governmental Service: None
Honors and Awards:
University of Delhi, Delhi, India, 1974 - 1976 University of Delhi, Delhi, India, 1976 - 1977 M.D. Anderson Cancer Center, 1999 - 2002 M.D. Anderson Cancer Center, 2003 - 2004 Robert M. Chamberlain Distinguished Mentor Award Postdoctoral Association Steering Committee M.D. Anderson Cancer Center, 2005 - 2006 M.D. Anderson Cancer Center, 2006 – 2011 Potu N. Rao Award for Excellence in Basic Science Division of Cancer Medicine Faculty Recognition & Award Program M.D. Anderson Cancer Center, 2007 - 2008 Research:
Grants and Contracts (past 5 years):

"Biochemical Strategies to Increase Leukemia Response" Varsha Gandhi, Principal Investigator
09/01/02-08/31/07, Annual direct costs: $175,000. The Leukemia & Lymphoma Society Translational Research Grant 6208-05, years 01-03. "DNA Independent Strategy to Target CLL" Varsha Gandhi, Principal Investigator
10/01/04-09/30/07, Annual direct costs: $123,120.
The Leukemia & Lymphoma Society Translational Research Grant 6234-07, years 01-03. "BLyS-Gelonin: A Targeted Therapeutics for CLL" Varsha Gandhi, Principal Investigator
10/01/06-09/30/09, Annual direct costs: $180,000.
NIH RO1-CA85915, years 05-09.
"Adenosine analogs: Therapeutics for Hematologic Cancers" Varsha Gandhi, and Steve Rosen, Principal Investigators
10/01/05-09/30/10, Annual direct costs: $240,000. NIH RO1-CA85915-Supplement-1, years 01-03. "Minority Graduate Student Supplement" Varsha Gandhi, Principal Investigator
09/01/07-08/31/10, Annual direct costs: $33,440. Center for Targeted Therapy Disease-Specific Grant Program "Targeting Met Tyrosine Kinase in Multiple Myeloma"" Varsha Gandhi, Principal Investigator
04/01/08-03/31/10, Annual direct costs: $50,000. Clofarabine: Cytarabine Activation for Leukemia Response Varsha Gandhi & Stefan Faderl, Co Principal Investigator
09/01/03-08/31/05, Annual direct costs: $200,000. Hagop Kantarjian, Principal Investigator Project 3: “Concerted Blockade of Oncoprotein Activity" Varsha Gandhi, Co-Principal investigator
09/01/03-08/31/08, Annual direct costs: $181,090. NIH P50-SPORE- CA100632-Supplement-1, years 01-04. "Minority Graduate Student Supplement" Varsha Gandhi, Principal Investigator
09/01/08-08/31/11, Annual direct costs: $33,440. "Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Leukemia", Hagop Kantarjian, Principal Investigator Varsha Gandhi, Pharmacology Portion- Principal Investigator
09/30/02-09/29/05, Annual direct costs: $253,125. Michael Andreeff, Principal Investigator, Therapy of AML Project 3, "Pharmacokinetics and Pharmacodynamics in AML" Varsha Gandhi, Co-investigator (years 01-present)
04/01/00-03/31/06, Annual direct costs: $128,946. Chronic Lymphocytic Leukemia Research Consortium Thomas Kipps, Principal Investigator William Plunkett, Leader, Project 5, Novel Pharmacologic Agents in CLL Varsha Gandhi, Co-investigator
05/01/06-04/30/11, Annual direct costs: $151,000. "Development of 8-choloroadenosine for Multiple Myeloma" Varsha Gandhi, Co-investigator
Awarded 2000 - 2003 for toxicology and efficacy studies. Razelle Kurzrock, Principal Investigator “Phase I Studies of Targeted Anti-cancer Therapy" Varsha Gandhi, Co-investigator
02/01/03-01/31/08, Annual direct costs: $444,281. "Gordon Research Conf. on Nucleosides, Nucleotides, and Oligonucleotides" Varsha Gandhi, Principal Investigator, Annual direct costs: $10,000.
CLL Global Research Foundation US/European Alliance for the Therapy of CLL “Targeting anti-apoptotic proteins in CLL” Varsha Gandhi, Principal Investigator
03/01/08- 02/28/10, Annual direct costs: $150,000. CLL Global Research Foundation “Transcription Inhibition to Target CLL” Varsha Gandhi, Principal Investigator
06/01/05- 05/31/07, Annual direct costs: $95,238. Varsha Gandhi, Principal Investigator
12/01/08-11/30/11, Annual direct costs: $143,885. NIH P50-SPORE- CA100632-Supplement-1, years 01-04. "Minority Graduate Student Supplement" Varsha Gandhi, Principal Investigator
10/01/08-09/30/12, Annual direct costs: $33,440. "8-Cl-Ado for treatment of CLL" William G. Wierda, Principal Investigator Varsha Gandhi, Principal Investigator, pharmacology portion
5/01/09-04/30/11, Annual direct costs: $250,000, pharmacology cost: $100,000.
CLL Global Research Foundation
“Effect of Microenvironment on Mcl-1 in CLL cells”
Varsha Gandhi, Principal Investigator
09/01/09- 08/31/11, Annual direct costs: $95,238. Project 3: “Development of 8-Cl-Adenosine" Varsha Gandhi, Principal investigator
09/01/09-08/31/12, Annual direct costs: To be determined. Project 4: “Targeting Met for Multiple Myeloma" Varsha Gandhi, Principal investigator
01/01/10-12/31/15, Annual direct costs: $180,000. Funded Private Agency Grant Support (past 5 years):
Golfers Against Cancer “Mechanism Based Combination for Treatment of Acute Leukemia” Varsha Gandhi, Principal Investigator
01/01/03- 12/31/04, Total direct costs: $200,000, (with matching funds).
Aventis Drug Development Award
Varsha Gandhi, Principal Investigator
12/15/03- 12/14/04, Total direct costs: $40,000 Funded Sponsored Research Agreements (past 5 years):
Bioenvision Ltd., Edinburgh, UK "Preclinical studies with gossypol" Varsha Gandhi, Principal Investigator
07/01/07 – 12/31/08, Total direct costs: $60,000. MundiPharma International Ltd., Cambridge, UK "Forodesine-induced apoptosis of CLL B cells: Effects of the microenvironment" Varsha Gandhi, Principal Investigator
07/01/07 – 12/31/08, Total direct costs: $40,000. Cephalon, Inc. Frazer, PA "Preclinical development of bedamustine" Varsha Gandhi, Principal Investigator
07/01/08 – 06/30/09, Total direct costs: $60,000. Cephalon, Inc. Frazer, PA "Phase I/II study of bendamustine in patients with acute leukemias and high-risk MDS" Varsha Gandhi, Principal Investigator
10/01/08 – 09/30/10, Total direct costs: $2,000/patient x 40 = $80,000. BioCryst Pharmaceuticals, Inc., Birmingham, AL "Preclinical investigations with BCX-1777" Varsha Gandhi, Principal Investigator
04/01/02 – 03/31/07, Total direct costs: $58,000. "Metabolic Strategies to Expand the Use of Nipent" Varsha Gandhi, Principal Investigator
05/01/01-04/30/05, Total direct costs: $130,000. Cephalon, Inc. Frazer, PA "Phase I/II study of bendamustine in combination with fludarabine in patients with chronic lymphocytic leukemia” Varsha Gandhi, Principal Investigator
09/01/09 – 08/31/11, Total direct costs: $3,000/patient x 30 = $90,000. Funded Clinical Protocols for Laboratory Endpoints (Past 5 years): Glaxo Wellcome Inc. Research Triangle Park, NC "Phase II Study of 506U78 in fludarabine refractory patients with chronic lymphocytic leukemia. (protocol PGAA2001)" Varsha Gandhi, Principal Investigator
2/1/99-1/31/05, Total direct costs: $90,415. BioCryst Pharmaceuticals, Inc., Birmingham, AL "Pharmacological investigations during phase I study with BCX-1777" Varsha Gandhi, Principal Investigator
11/1/01 – 10/31/05, Total direct costs: $2,000/patient x 71 = $142,000. BioCryst Pharmaceuticals, Inc., Birmingham, AL "Pharmacological investigations during B-CLL study" Varsha Gandhi, Principal Investigator
08/1/05 – 07/31/08, Total direct costs: $2,000/patient x 30 = $60,000. BioCryst Pharmaceuticals, Inc., Birmingham, AL " Pharmacodynamic investigations during Phase I/II, multi-center, open-label, repeat-dose study of Forodesine Hydrochloride infusion in patients with B-cell acute lymphoblastic leukemia " Varsha Gandhi, Principal Investigator
1/1/06 – 12/31/06, Total direct costs: $2,500/patient x 10 = $25,000. Genzyme Oncology, Inc. "Pharmacokinetic and pharmacodynamic investigations during phase I study of weekly clofarabine for patients with CLL" ID2004-0134 Varsha Gandhi, Principal Investigator
03/1/05 – 02/28/07, Total direct costs: $48,000. Genzyme Oncology, Inc. “Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children with Relapsed or Refractory Acute Leukemias” In collaboration with The Sidney Kimmel Cancer Center at Johns Hopkins Varsha Gandhi, Principal Investigator
06/01/06 – 05/31/07, Total direct costs: $34,000. Glaxo Wellcome Inc. Research Triangle Park, NC "Phase I Study of 506U78 Administered in Combination with Fludarabine on a Day 1, 3, and 5 Schedule (protocol PGAA1005)" Varsha Gandhi, Principal Investigator
7/1/98-8/31/02, Total direct costs: $60,940. Unfunded Clinical Protocols (Past 5 years): Varsha Gandhi, Collaborator
POG protocol- PI Stacey Berg, Texas Children’s Hospital, Phase II Study of Compound
506 in Patients with Refractory T-Cell Malignancies - A POG/CCG Intergroup Study,
2000-2004.
Varsha Gandhi, Collaborator
ID99-370, PI Deborah Thomas, Compound 506U78 (NSC 686673) in Patients with
Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell
Lymphoblastic Lymphoma , 1999-present.
Varsha Gandhi, Co investigator
AML-97 – SJCRH protocol- PI Raul Ribiero, St. Jude Children’s Research Hospital,
Phase II Study of Treatment for Newly Diagnosed Patients with Acute Myeloid
Leukemia or Myelodysplasia, 1998-2003.
Varsha Gandhi
, Collaborator
DM93-036- PI Hagop Kantarjian, Phase I Study of 2-Chloro-2' -Fluoro-Deoxy-9-B-D-
Arabinofuranosyladenine (C1-F-ARA-A; Clofarabine) in Solid and Hematologic
Malignancies. 1999-2002.
Varsha Gandhi
, Collaborator
ID04-0183- PI Stefan Faderl, Randomized Phase II Study of Clofarabine Alone Versus
Clofarabine in Combination with Low-Dose Cytarabine (ara-C) in Previously Untreated
Patients > 60 Years with Acute Myeloid Leukemia and High-Risk Myelodysplastic
Syndrome (MDS). 2004-present.
Varsha Gandhi, Collaborator
DM99-225- PI Michael Keating, Phase II Study to Assess the Efficacy of 2-Chloro-
2'Fluoro-Deoxy-9-B-D-Arabinofuranosyladenine (C1-F-Ara-A; Clofarabine) in Patients
with Chronic Lymphocytic Leukemia who are Refractory to Fludarabine and Alkylator
Therapy. 2001-2003.
Varsha Gandhi, Collaborator
DM03-0139- PI Stefan Faderl, A Phase II Study of Clofarabine in Combination with
Cytarabine (Ara-C) in Patients > 50 years with Newly Diagnosed and Previously
Untreated Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome
(MDS) (>10% Bone Marrow Blasts) 2004-present.

Varsha Gandhi
, Collaborator
ID00-038- PI Hagop Kantarjian, Phase II Study of 2-Chloro-2'-Fluoro-Deoxy-9- β-D-
Arabinofuranosyladenine (CI-F-ara-A; Clofarabine) in Acute Leukemia and
Myelodysplastic Syndrome (MDS) Refractory to Therapy or in Relapse. 2000-2003.

Varsha Gandhi
, Collaborator
ID01-168. PI Stefan Faderl, Phase I Study of a Continuous Infusion Schedule of (E)-
2'deoxy-2'-(fluoromethylene) Cytidine (Tezacitabine, FMdC) in Hematologic
Malignancies 2001-2003.

Varsha Gandhi
, Collaborator
DM99-209- PI Stefan Faderl, A Study of (E)-2'deoxy-2'-fluoromethylene) Cytidine
(FMdC) in Hematologic Malignancies 2000-2002.

Varsha Gandhi
, Collaborator
ID00-102- PI Hagop Kantarjian, Tiazofurin Phase III Study in Patients with Chronic
Myelogenous Leukemia (CML) in Accelerated Phase or in BC, 2000-2003.
Varsha Gandhi
, Collaborator
2005-0535- PI Hagop Kantarjian, Phase II randomized schedules of intravenous
clofarabine in Myelodysplastic syndrome (MDS), 2006-present.

Varsha Gandhi
, Collaborator
2006-0654- PI Hagop Kantarjian, A phase II study of single agent clofarabine in
previously untreated patients with acute myelogenous leukemia (AML) for whom
standard induction of chemotherapy is unlikely to be of benefit, 2006-present.

Varsha Gandhi
, Collaborator
2005-0536- PI Hagop Kantarjian, Phase II study of oral clofarabine in myelodysplastic
syndrome (MDS), 2006-present.

Varsha Gandhi
, Co-principal Investigator
2004-0144- PI William Wierda, Phase I study of 8-chloro-adenosine in previously
treated patients with chronic lymphocytic leukemia, 2007-present.
Grant Reviewer/Service on NIH/Other Study Sections: New Investigator Award Grant, Alberta Cancer Board Special Review Group, Merit Review Applications NIH - Developmental Therapeutics Program NIH, Basic Mechanisms of Cancer Therapeutics Study Section Basic & Preclinical – Drug Discovery Cluster Study Section Chair, study section NIH, Drug Discovery and Molecular Pharmacology Study Section ZRG1 OTC-L Drug Discovery ARRA CR Study Section
Publications:

a. Peer-reviewed Articles:
Sehgal, C. B. and Parikh, V. A technique for making aniline blue black stained
preparations permanent. J. Cytol. Genet. 12:99-101, 1977.
Sehgal, C. B. and Gandhi, V. Cytochemical studies on the origin and development of
protein bodies in the cotyledons of pigeon pea. J. Cytol. Genet. 15:196-201, 1980.
Sehgal, C. B. and Gandhi, V. Breakdown of protein bodies in cotyledons of pigeon
pea during germination. Indian J. Exp. Biol. 19:341-344, 1981.
Gandhi, V., Sharp, Z. D. and Procunier, J. D. Analysis of Y chromosome nucleolar
organizer mutants in Drosophila melanogaster. Biochem. Biophys. Res. Comm.
104:778-784, 1982.
Sharp, Z. D., Gandhi, V., Kalumuck, K. and Procunier, J. D. A rapid method for
determining r-RNA gene numbers. Drosophila Information Service 58:170, 1982.
Venketeswaran, S. and Gandhi, V. Mass propagation and genetic improvement of
forest trees for biomass production by tissue culture. Biomass 2:5-15, 1982.
Gandhi, V. Tissue culture of chinese tallow - an euphorbiaceous tree. Current Sci.
52:365-367, 1983.
Sharp, Z. D., Gandhi, V. and Procunier, J. D. X chromosome nucleolus organizer
mutants which alter major type I repeat multiplicity in Drosophila melanogaster. Mol.
Gen. Genet. 190:438-443, 1983.
Sehgal, C. B. and Gandhi, V. Studies on the endosperm of Cajanus cajan with special
emphasis on the function. Phytomorphology 35:201-206, 1985.
Sehgal, C. B. and Gandhi, V. Histology and histochemistry of pericarp of grain
legumes: Cajanus cajan, Vigna mungo and Vigna radiata. Cytologia 51:333-339,
1986.
Sehgal, C. B. and Gandhi, V. Histological and histochemical studies on the cotyledons
of some legumes. I. Changes during seed development. Phytomorphology 37:9-16,
1987.
Sehgal, C. B., Gandhi, V. and Varma, B. Histological and histochemical studies on the
cotyledons of some legumes. II. Reserve metabolites during seed development.
Cytologia 52:847-858, 1987.
Gandhi, V., Danhauser, L. and Plunkett, W. Separation of 1-ß-D-
arabinofuranosylcytosine 5'-triphosphate and 9-ß-D-arabinofuranosyl-2-fluoroadenine
5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
J. Chromatography 413:293-299, 1987.
Danhauser L., Plunkett W., Liliemark J., Gandhi V., Iacoboni S. and Keating M.
Comparison between the plasma and intracellular pharmacology of 1-ß-D-
arabinofuranosylcytosine and 9-ß-D-arabinofuranosyl-2-fluoroadenine 5'-
monophosphate in patients with relapsed leukemia. Leukemia 1:638-643, 1987.
Gandhi V. and Plunkett W. Modulation of arabinosylnucleoside metabolism by
arabinosylnucleotides in human leukemia cells. Cancer Res. 48: 329-334, 1988.
Gandhi, V. and Plunkett, W. Interaction of arabinosyl nucleotides in K562 human
leukemia cells. Biochemical Pharmacology 38:3551-3558, 1989.
Gandhi, V., Nowak, B., Keating, M. J. and Plunkett, W. Modulation of
arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from
patients with chronic lymphocytic leukemia: implications for combination therapy.
Blood 74:2070-2075, 1989.
Sehgal, C. B. and Gandhi, V. Histological and histochemical studies on the cotyledons
of some legumes. III. Nucleic acids during seed development. Acta Bot. Indica 17:94-
100, 1989.
Gandhi, V. and Plunkett, W. Modulatory activity of 2',2'-difluorodeoxycytidine on the
phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 50:3675-
3680, 1990.
Sehgal, C. B. and Gandhi, V. Quantification of nucleic acids and some metabolites
during embryo development in Vigna mungo (L.) hepper and Vigna radiata (L.)
wilczek. Acta Bot. Indica 18:199-203, 1990.
Gandhi, V., Keating, M. J., Estey, E. and Plunkett, W. Fludarabine infusion potentiates
arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic
leukemia. Cancer Res. 52:897-903, 1992.
Gandhi, V. and Plunkett, W. Cell cycle specific metabolism of arabinosyl nucleosides
in K562 human leukemia cells. Cancer Chemother. Pharmacol. 31:11-17, 1992.
Gandhi, V., Shewach, D., Keating, M. J., and Plunkett, W. Inhibition of
fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother. Pharmacol. 31:193-199, 1992. Gandhi, V., Estey, E., Keating, M. J. and Plunkett, W. Fludarabine potentiates
metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during
therapy. J. Clin. Oncol. 11:116-124, 1993.
Estey, E., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H. and Keating, M.J.
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute
myelogenous leukemia. Leukemia Lymphoma 4:343-350, 1993.
Gandhi, V., Kemena, A., Keating, M.J., and Plunkett, W. Cellular pharmacology of
fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine
therapy. Leukemia Lymphoma 10:49-56, 1993.
Suki, S., Kantarjian, H., Gandhi, V., Estey, E., O'Brien S., Beran, M., Rios, M.B.,
Plunkett, W., Keating, M.J. Fludarabine and cytosine arabinoside in the treatment of
refractory acute lymphocytic leukemia. Cancer 72:2155-2160, 1993.
Gandhi, V., Robertson, L.E., Keating, M.J., and Plunkett, W. Combination of
fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia:
Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer
Chemother. Pharmacol. 34:30-36, 1994.
Gandhi, V., Du, M., Kantarjian, H.M., and Plunkett, W. Effect of granulocyte-
macrophage colony-stimulating factor on the metabolism of arabinosylcytosine
triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Leukemia 8:1463-1468, 1994.
Gandhi, V., Estey, E., Du, M., Nowak, B.J., Keating, M. J. and Plunkett, W. Effect of
granulocyte colony stimulating factor on the cellular metabolism of cytarabine and
fludarabine during therapy of acute myelogenous leukemia. Clin. Cancer Res. 1:169-
178, 1995.
Gandhi, V., Mineishi, S., Huang, P., Chapman, A.J., Yang, Y., Chen, F., Nowak, B.,
Chubb, S., Hertel, L.W., and Plunkett, W. Cytotoxicity, metabolism, and mechanisms
of action of 2', 2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res.
55: 1517-1524, 1995.
Gandhi, V., Estey, E., Keating, M.J., Chucrallah, A., and Plunkett, W.
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous
leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood
87:156-164, 1996.
Seymour, J.F., Huang, P., Plunkett, W., and Gandhi, V. Influence of fludarabine on
pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous
infusion schedule. Clin. Cancer Res. 2:653-658, 1996.
Gandhi, V., Plunkett, W., and Zwelling, L.A. The effect of 9-ß-D-
arabinosfuranosyl-2-fluoroadenine and 1-ß-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother. Pharmacol. 38:261-268, 1996. Gandhi, V., Andreeff, M., Beran, M., Kantarjian, H., Koller, C.A.,
O'Brien, S., Plunkett, W., and Estey, E. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569, 1996. Gandhi, V., Legha, J., Chen, F., Hertel, L.W., and Plunkett, W. Excision of 2',2'-
difluorodeoxycytidine monophosphate residues from DNA. Cancer Res. 56:4453-4459,
1996.
Gandhi, V., Huang, P, Chapman, A., Chen, F., and Plunkett, W. Incorporation of
fludarabine and arabinosylcytosine 5'-triphosphates by DNA polymerase α: Affinity,
Interaction, and Consequences. Clin. Cancer Res. 3:1347-1355, 1997.
Gandhi, V., Estey, E., Du, M., Keating, M.J., and Plunkett, W. Minimum dose of
fludarabine for maximal modulation of arabinosylcytosine triphosphate in human
leukemia blasts during therapy. Clin. Cancer Res. 3:1539-1545, 1997.
Rodriguez, C.O., Jr., Legha, J.K., Estey E., Keating, M.J., Gandhi, V. Pharmacological
and biochemical strategies to increase the accumulation of arabinofuranosylguanine
triphosphate in primary human leukemia cells. Clin. Cancer Res. 3:2107-2113, 1997.
Gandhi, V., Plunkett, W., Kantarjian, H., Talpaz, M., Robertson, L.E., and O’Brien, S.
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused
hydrea during phase I clinical trial in chronic myelogenous leukemia. J. Clin. Oncol.
16:2321-2331, 1998.
Gandhi, V., Xu, Y-Z., and Estey, E. Accumulation of arabinosyluracil 5'-triphosphate
during arabinosylcytosine therapy in circulating leukemia blasts of patients with acute
myelogenous leukemia. Clin. Cancer Res. 4:1719-1726, 1998.

42. Gandhi, V., Plunkett, W., Rodriguez, C.O., Jr., Nowak, B.J., Du, M., Ayres, M., Kisor,
D.F., Mitchell, B.S., Kurtzberg, J., Keating, M.J. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. 16:3607-3615, 1998.
43. Aguayo, A., Cortes, J.E., Kantarjian, H.M., Beran, M., Gandhi, V., Plunkett, W.,
Kurtzberg, J., and Keating, M.J. Complete hematologic and cytogenetic response to 2-amino-9-ß-D-arabinosyl-6-methoxy-9H-guanine (GW506U78) in a patient with chronic myelogenous leukemia and T-cell blastic phase: A case report and review of literature. Cancer, 85:58-64, 1999. 44. Dumontet, C., Fabianowska-Majewska, K., Mantincic, D., Callet Bauchiu, E., Tigaud, I., Gandhi, V., Lepoivre, M., Peters, G.J., Rolland, M.O., Wyczechowska, D., Fang, X.,
Gazzo, S., Voorn, D.A., Vanier-Viornery, A., and Mackey, J. Common resistance
mechanism to deoxynucleoside analogues in variants of the human erythroleukemic line
K562. Brit. J. Haematol. 106:78-85, 1999.
45. Rodriguez, C.O., Jr. and Gandhi, V. Arabinosylguanine-induced apoptosis of T-
lymphoblastic cells: Incorporation into DNA is a necessary step. Cancer Res. 59:4937-4943, 1999. 46. Giles, F.G., O’Brien, S. M., Santini, V., Gandhi, V., Plunkett, W., Seymour, J.F.,
Robertson, L.E., Kantarjian, H.M., and Keating, M.J. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study. Leukemia Lymphoma 36:57-65, 1999. 47. Kisor, D.F , Plunkett, W., Kurtzberg, J., Mitchell, B.S., Hodge, J.P., Ernst, T., Keating , M.J, and Gandhi, V. The pharmacokinetics of 506U78 and ara-G in pediatric and adult
patients during a Phase I study of 506U78 for the treatment of refractory hematologic
malignancies. J. Clin. Oncol. 18: 995-1003, 2000.
48. Rodriguez, C.O., Jr., Plunkett, W., Paff, M. T., Du, M., Nowak, B., Ramakrishna P., Keating, M.J., Gandhi, V. A high-pressure liquid chromatography method for the
determination and quantitation of arabinosylguanine triphosphate and fludarabine
triphosphate in human cells. J. Chromatography B, 745:421-430, 2000.
49. Gandhi, V. Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez, Jr. C.O.,
Ramakrishna, P., Rosner, G.L., Hodge, J.P., O’Brien, S., and Keating, M.J. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J. Clin. Oncol., 19:2142-2152, 2001. 50. Gandhi, V., Ayres, M., Halgren, R.G., Krett, N.L., Newman, R.A., Rosen, S.T.
Metabolism and action of 8-Chloro-cAMP and 8-Chloro-adenosine in multiple myeloma. Cancer Res. 61:5474-5479, 2001. 51. Patel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M.A., Plager, C.,
Plunkett, W., and Benjamin, R.S. Phase II Clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose-rate on gemcitabine triphosphate accumulation. J. Clin. Oncol., 19:3483-3489, 2001. 52. Gandhi, V., Plunkett, W., Du, M., Ayres, M., and Estey, E. Prolonged infusion of
gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J. Clin. Oncol., 20: 665-673, 2002. 53. Zhou, Y., Achanta, G., Pelicano, H., Gandhi, V., Plunkett, W., and Huang, P. Action of
(E)-2'-Deoxy-2'-(fluoromethylene)cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response. Mol. Pharmacol. 61: 222-229, 2002. 54. Gandhi, V. and Plunkett, W. Cellular and clinical pharmacokinetics of fludarabine.
Clinical Pharmacokinetics, 41:93-103, 2002. 55. Gandhi, V., Chen, W., Ayres, M., Rhie, J., Madden, T. L., and Newman, R.A. Plasma
and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother. Pharmacol., 50:85-94, 2002. 56. Rodriguez, C.O., Jr., Mitchell B.S., Eriksson, S., and Gandhi, V. Arabinosylguanine is
phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res., 62:3100-3105, 2002. 57. Crews, K.R., Gandhi, V., Srivastava, D.K., Razzouk, B.I., Tong, X., Behm, F.G.,
Plunkett, W., Raimondi, S., Pui, C-H., Rubnitz, M.V., Stewart, C.F., and Ribeiro, R.C. Evaluation of continuous infusion versus bolus infusion of cytarabine in combination with cladribine in pediatric acute myeloid leukemia: An interim analysis. J. Clin. Oncol., 20:4217-4224, 2002. 58. Lin-Lee, Y-C, Nakamura, S., Gandhi, V., Curley, S.A., Stuber, D., Burkot T., and Kuo,
M. T. Prolonged stability of recombinant protein and sustained prodrug cell killing using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol. Cancer Therapeutics, 1:461-467, 2002. 59. Stellrecht, C. and Gandhi, V. A method for concurrent isolation of ribosomal,
messenger, and low molecular weight RNA from cells. Biotechnique, 33:1122-24, 2002. 60. Chadi, N., Gajria, D., Krett, N., Gandhi, V., Ghias, K., and Rosen, S. Caspase
activation is required for gemcitabine activity in multiple myeloma cell lines. Mol. Cancer Therapeutics, 1:1221-1227, 2002. 61. Sharma, G., Scherthan, H., Dhar, S., Gupta, A., Wang, H., Gandhi, V., Iliakis, G.,
Young, C.S., and Pandita, T.K. TERT expression reduces spontaneous chromosome damage and enhances DNA repair. Oncogene, 22:131-146, 2003. 62. Kantarjian, H. Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O’Brien, S.,
Ibrahim, N., Khuri, F., Du, M., Rios, M.B., Plunkett, W., and Keating M.J. Phase I
clinical and pharmacology study of clofarabine (chloro-2’-fluoro-deoxy-9-beta-D-
arabinofuranosyladenine) in patients with solid and hematologic cancers, J Clin. Oncol,
21:1167-1173, 2003.
63. Rodriguez, C. O., Stellrecht, C., and Gandhi, V. Mechanisms for T-cell selective
cytotoxicity of arabinosylguanine. Blood, 102:1842-1848, 2003. (Accompanied with an editorial) 64. Giles, F.J., Kantarjian, H.M., Fracasso, P.M., Cortes, J.E., Verstovsek, S., Brown, R.A., Alvarado, Y., Thomas, D.A., Faderl, S., Garcia-Manero, G., Wright, L.P., Samson, T.,
Cahill A., Lambert, P., Plunkett, W., Sznol, M., DiPersio, J.F., and Gandhi, V. Phase I
and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in
patients with advanced leukemia. Leukemia Res. 27:1077-1083, 2003. (Accompanied
with an editorial)
65. Kantarjian, H., Gandhi, V., Cortes J., Verstovsek, S., Du, M., Garcia-Manero, G.,
Faderl, S., O’Brien, S., Jeha S., Davis, J., Shaked, Z., Keating, M., Plunkett, W., Freireich, EJ. Phase II clinical and pharmacology study of clofarabine inpatients with refractory or relapsed acute leukemias. Blood, 102:2379-2386, 2003. 66. Flanagan, S.A., Gandhi, V., Secrist, J.A., and Meckling, K.A. The novel nucleoside
transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem. Pharmacol., 66:733-737, 2003. 67. Stellrecht, C., Rodriguez, C.O., Ayres, M., and Gandhi, V. RNA-directed actions of 8-
chloro-adenosine in multiple myeloma. Cancer Res. 63:7968-7974, 2003. 68. Gandhi, V., Kantarjian, H., Faderl, S., Bonate, P., Du, M., Ayres, M., Rios, M.B.,
Keating, M.J., and Plunkett, W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical Cancer Res., 9:6335-6342, 2003 (This was mentioned on the cover of the journal). 69. Jeha, S. Gandhi, V., Chan, K.W., McDonald, L., Ramirez, I., Madden, R., Rytting, M.
Brandt, M., Keating, M., Plunkett, W., and Kantarjian, H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103:784-789, 2004. 70. Krett, N.L., Ayres, M., Nabhan, V., Ma, C., Nowak, B., Nawrocki, S., Rosen, S., and Gandhi, V. Gemcitabine is a potent cytotoxic agent for multiple myeloma. Cancer
Chemother. Pharmacol., 54:113-121, 2004.
71. Krett, N. L., Davies, K.M., Ayers, M., Ma, C., Nabhan, C., Gandhi, V., and Rosen, S.T.
8-Amino-Adenosine is a potential therapeutic agent for multiple myeloma. Molecular Cancer Therapeutics, 3: 1411-1420, 2004. 72. Bonate, P.L., Craig, A., Gaynon, P., Gandhi, V., Jeha, S., Kadota, R., Lam, G.N.,
Plunkett, W., Razzouk, B., Rytting, M., Steinherz, P., and Weitman, S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J. Clin Pharmacol. 44:1309-1322, 2004. 73. Faderl, S., Gandhi, V., O’Brien, S., Bonate, P., Cortes, G., Estey, E., Beran, M.,
Wierda, W., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Giles, F.G., Du, M., Kwari, M., Keating, M.J., Plunkett, W., and Kantarjian, H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias, Blood, 105:940-947, 2005. 74. Cooper, T., Ayres, M., Nowak, B., and Gandhi, V. Biochemical modulation of
cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol. 55:361-368, 2005. 75. Balakrishanan, K., Stellrecht, C., Genini, D., Ayres, M., Wierda, W., Keating, M.J., Leoni, L.M., and Gandhi, V. Cell death of bioenergetically compromised and
transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105:4455-
4462, 2005.
76. Ghias, K., Ma, C., Gandhi, V., Platanias, L.C., Krett, N.L., and Rosen, S.T. 8-Amino-
adenosine induces loss of phosphorylation of p38 mitogen activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma. Mol Cancer Ther. 4:569-577, 2005. 77. Kurtzberg, J., Ernst, T.J., Keating, M.J., Gandhi, V., Hodge, J.P., Kisor, D.F., Lager,
J.J., Stephens, C., Levin, J., Krenitsky, T., Elion, G., and Mitchell, B.S. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 23:3396-3403, 2005. 78. Jabbour, E., Verstovsek, S., Gandhi, V., Cortes, J., Giles, F., O’Brien S, Plunkett, W.,
Garcia-Manero, G., Jackson, E., Kantarjian, H., Andreeff, M. 2-chlorodeoxyadenosine and cytarabine combination is effective and safe therapy for idiopathic hypereosinophilic syndrome. Cancer, 104:541-546, 2005. 79. Gandhi, V., Kilpatrick, J.M., Plunkett, W., Ayres, M., Harman, L., Du, M., Bantia, S.,
Davisson, J., Wierda, W.G., Faderl, S., Kantarjian, H., and Thomas, D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor forodesine (BCX-1777). Blood, 106:4253-4260, 2005. 80. Balakrishnan, K., Wierda, W., Keating, M.J., and Gandhi, V. Mechanisms of cell
death of CLL lymphocytes by RNA-directed agent 8-amino-adenosine. Clin. Cancer Res. 11: 6745-6753, 2005. 81. Chen, R., Keating, M.J., Gandhi, V., and Plunkett, W. Flavopiridol-induced apoptosis
in chronic lymphocytic leukemia cells through the transcriptional inhibition of anti-apoptotic proteins. Blood, 106:2513-2519, 2005. 82. Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., and
Plunkett, W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood, 107:2517-2524, 2006. 83. Gandhi, V., Plunkett, W., Bonate, P.L., Du, M., Nowak, B., Lerner, S., and Keating,
M.J. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia (CLL): Strategy for treatment. Clin. Cancer Res., 12:4011-4017, 2006. 84. Balakrishnan, K., Nimmanapalli, R., Ravandi, F., Keating, M.J., and Gandhi, V.
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 108:2392-2398, 2006. 85. Chandra, D., Bratton, S.B., Person, M.D., Tian, Y., Martin, A.G., Ayres, M., Fearnhead, H.O., Gandhi, V., Tang, D.G. Intracellular nucleotides act as critical prosurvival
factors by binding to cytochrome C and inhibiting formation of the Apaf-1 apoptosome.
Cell, 125:1333-1346, 2006.
86. Vega, B-S., Krett N.L., Rosen, S.T., and Gandhi, V. Glucocorticoid receptor
transcriptional isoforms and resistance in multiple myeloma cells. Mol. Cancer Therapeutics, 5:3062-70, 2006. 87. Chen, R., Gandhi, V., and Plunkett, W. A sequential blockade strategy for the design
of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res., 66:10959-10566, 2006. 88. Nimmanapalli, R., Lyu, M-A., Du M., Keating M.J., Rosenblum, M., and Gandhi, V.
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R positive CLL cells. Blood, 109:2557-2564, 2007. 89. Flanagan, S.A., Gandhi, V., and Meckling, K.A. NB4 cells undergo apoptosis when
exposed to excess extracellular guanosine. Leukemia and Lymphoma, 48:1816-1827, 2007. 90. Karp J.E., Ricklis, R.M., Balakrishnan, K., Briel, J., Greer, J., Gore, S.D., Smith, B.D., McDevitt, M.A., Carraway, H., Levis, M.J., and Gandhi, V. A phase I clinical-
laboratory study of clofarabine followed by cyclophosphamide for adults with
refractory acute leukemias. Blood, 110:1762-1769, 2007.
91. Stellrecht, C., Phillip, C., Gomez, F., and Gandhi, V. Multiple myeloma cell killing by
depletion of the MET receptor tyrosine kinase. Cancer Res., 67:9913-9920, 2007. 92. Gandhi, V. Questions about gemcitabine dose-rate: Answered or unanswered? J. Clin.
93. Lamba, J.K., Crews, C., Pounds, S., Schuetz, E.G., Gresham, J., Gandhi, V., Plunkett,
W., Rubnitz, J., and Ribeiro, R. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J. Pharmacol. Exp. Therap. 323: 935-945, 2007.
94. Chen, L., Stellrecht, C., and Gandhi, V. A polyadenylation inhibitor, cordycepin,
decreases MET transcript levels and induces cell death in multiple myeloma cells. British J Hematol., 140:682-691, 2008. 95. Gandhi, V., Tam, C., O’Brien, S, Jewell, RC, Rodriguez, Jr., C.O., Lerner, S., Plunkett,
W., and Keating, M.J. Phase I trial of nelarabine in indolent leukemias. J. Clin. Oncol., 26:1098-1105, 2008. 96. Chen L., Plunkett, W., and Gandhi, V. Polyadenylation inhibition by the triphosphates
of deoxyadenosine analogues. Leukemia Res., 32:1573-1581, 2008. 97. Nimmanapalli, R., Gerbino E., Dalton, W.S., Gandhi, V. And Alsina M. HSP70
inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. British J Hematol., 142:551-561, 2008. 98. Balakrishnan, K., Wierda, W., Keating, M.J., and Gandhi, V. Gossypol, a BH3
mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 112:1971-1980, 2008. 99. Borthakur, G., Kantarjian, H., Wang, X., Plunkett, W., Gandhi, V., Faderl, S., Garcia-
Manero, G., Ravandi, F., Pierce, S., and Estey, E.H. Treatment of core binding factor acute myelogenous leukemia with fludarabine, cytarabine and granulocyte colony stimulating factor results in improved event-free survival. Cancer, 113:3181-3185, 2008. 100. Gandhi, V., Balakrishnan, K., Chen L. Mcl-1: The 1 in CLL. Blood, 112:5538-5540,

101. Balakrishnan, K., Burger, J.A., Wierda, W., and Gandhi, V. AT-101 induces apoptosis
in CLL B-cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood, 113:149-153, 2009. 102. Phillip, C. J., Stellrecht, C.M., Nimmanapalli, R., and Gandhi, V. Targeting MET
Transcription as a Therapeutic Strategy in Multiple Myeloma. Cancer Chemother. Pharmacol., 63:587-597, 2009. 103. Guo, Y., Köck, K., Ritter, C.A., Chen, Z-S., Grube, M., Jedlitschky, G., Illmer, T., Ayres, M., Beck, J.F., Siegmund, W., Ehninger, G., Gandhi, V., Kroemer, H.K., Kruh,
G.D., Schaich, M. Expression of ABCC type nucleotide exporters in blasts of adult
acute myeloid leukaemia: relation to long term survival. Clin. Cancer Res. 15:1762-
1769, 2009.
104. Vega, B-S. and Gandhi, V. Glucocorticoid resistance in multiple myeloma cell kill is
regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). British J Hematol., 144:856-864, 2009. 105. Rubnitz, J.E., Crews, K.R., Pounds, S., Yang, S., Campana, D., Gandhi, V., Raimondi,
S.C., Downing, J.R., Razzouk, B.I., Pui, C-H., Ribeiro, R.C. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St. Jude AML97 trial. Leukemia ePub Feb. 2009. 106. Chen, R., Wierda, W.G., Chubb, S., Hawtin, R.E., Fox, J.A., Keating, M.J., Gandhi, V.,
and Plunkett, W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood, 113:4637-4645, 2009. 107. Cervantes-Gomez, F. Nimmanapalli, R., Gandhi, V. Transcription inhibition of heat
shock proteins: A strategy for combination of 17-allylamino-17-demethoxy-geldanamycin and actinomycin D. Cancer Res., 69:3947-3954, 2009. 108. Chen, L.S., Nowak, B.J., Ayres, M.L., Krett, N.L., Rosen, S.T., Zhang, S.*, Gandhi,
V.* Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem.
Pharmacol., 78:583-591, 2009. (* equal contributions).
109. Quiroga, M.P., Balakrishnan, K., Kurtova, A.V., Sivina, M., Keating, M.J., Wierda, W.G., Gandhi, V., and Burger, J.A. B cell antigen receptor signaling enhances chronic
lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk
inhibitor, R406. Blood, 114:1029-1037, 2009.
110. Stellrecht, C., Arya, R., Ayres, M., and Gandhi, V. A unique RNA-directed nucleoside
analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res. Treat., in press, 2009. 111. Burger, J.A. and Gandhi, V. The lymphatic tissue microenvironments in chronic
lymphocytic leukemia: In vitro models and the significance of CD40-CD154 interactions. Blood, in press, 2009. 112. Chen, L.S., Redkar, S., Bearss, D., Wierda, W.G., and Gandhi, V. Pim kinase
inhibitor, SGI-1776, induces apoptosis in CLL lymphocytes. Blood, in press, 2009. Parikh, V. Suspensor in angiosperms. Botanica 25:84-90, 1975.
Parikh, V. The central cell of angiosperms. Botanica 27:52-58, 1977.
Venketeswaran, S., Gandhi, V., Romano, E. J. and Nagmani, R. Mass propagation of
selected trees for biomass by tissue culture. in NATO adv. Study Inst. Ser., Ser. A -
Life Sci. 67:191-204, 1983.
Plunkett W., Gandhi V., Chubb S., Nowak B., Heinemann V., Mineishi S., Sen A.,
Hertel L. W. and Grindey G. B. 2',2'-difluorodeoxycytidine metabolism and mechanism
of action in human leukemia cells. Nucleosides Nucleotides 8:775-785, 1989.
Plunkett, W., Huang, P. and Gandhi, V. Metabolism and action of fludarabine.
Seminars Oncol. 17(Suppl. 5):3-17, 1990.
Plunkett, W. and Gandhi, V. Pharmacokinetics of arabinosylcytosine. J. Infusional
Chemother. 2:169-176, 1992.
Plunkett, W. and Gandhi, V. Cellular pharmacodynamics of anticancer drugs.
Seminars Oncol. 20: 50-63, 1993.
Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Biochemical modulation of
arabinosylcytosine for therapy of leukemias. Leukemia Lymphoma 10:(Suppl.) 109-
114, 1993.
Plunkett, W., Gandhi, V., Huang, P., Robertson, L.E., Yang, L-Y., Gregoire, V., Estey,
E., Keating M.J. Fludarabine: pharmacokinetics, mechanisms of action, and rationales
for combination therapy. Seminars Oncol. 20 (Suppl 7): 2-12, 1993.
Keating, M.J., O’Brien, S., Robertson, L.E., Kantarjian, H., Dimopoulos, M.,
McLaughlin, P., Cabanillas, F., Gregoire, V., Yang, L-Y., Gandhi, V., Estey, E.,
Plunkett, W. New initiatives with fludarabine monophosphate in hematologic
malignancies. Seminars Oncol. 20 (Suppl 7): 13-20, 1993.
Gandhi, V. Fludarabine for treatment of adult acute myelogenous leukemia. Leukemia
Lymphoma 11 (Suppl 2):7-13, 1993.
Plunkett, W. and Gandhi, V. Cellular pharmacodynamics as a guide to leukemia
therapy. Cancer Bulletin 46:8-14, 1994.
Keating M.J., O'Brien S., Plunkett, W., Robertson, L.E., Gandhi, V., Estey E.,
Dimopoulos, M., Cabanillas, F., Kemena, A., Kantarjian H. Fludarabine phosphate: A
new active agent in hematologic malignancies. Seminars Hematol., 31: 28-39, 1994.
Keating M.J., McLaughlin P., Plunkett, W., Robertson, L.E., O'Brien S., Gandhi, V.,
Gregoire, V., Yang, L., and Cabanillas, F. Fludarabine: Present status and future
development in chronic lymphocytic leukemia and lymphoma. Annals Oncol., 5
(Suppl. 2): s79-s83, 1994.
Gandhi, V., Huang, P., and Plunkett, W. Fludarabine inhibits DNA replication: A
rationale for its use in the treatment of acute myelogenous leukemia. Leukemia
Lymphoma, 14 (Suppl. 2):3-9, 1994.
Plunkett, W. and Gandhi, V. Evolution of the arabinosides and the pharmacology of
fludarabine. Drugs 47(Suppl 6) 30-38, 1994.
Gandhi, V., Mineishi, S., Yang, Y., Huang, P., Chubb, S., Chapman, A.J., Nowak, B.J.,
Hertel, L.W., and Plunkett, W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and
effects on DNA synthesis in human leukemia cells. Sem. Oncol., 22 (Suppl. 11), 61-67,
1995.
Plunkett, W., Huang, P., Xu, Y-Z., Heinemann, V., Grunewald, R., and Gandhi, V.
Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Sem. Oncol.,
22 (Suppl. 11), 3-10, 1995.
Plunkett, W., Huang, P. and Gandhi, V. Preclinical characteristics of gemcitabine.
Anti-Cancer Drugs, 6 (Suppl. 6), 7-13, 1995.
Gandhi, V., Estey, E. H., Keating, M. J., and Plunkett, W. Intracellular
pharmacodynamics in leukemia therapy. Japanese J. Clin. Hematol., 37:369-379, 1996.
Plunkett, W., Huang, P., Searcy, C.E., and Gandhi, V. Gemcitabine: Preclinical
pharmacology and mechanisms of action. Sem. Oncol., 23 (Suppl. 10), 3-15, 1996.
Plunkett, W. and Gandhi, V. Pharmacology of purine nucleoside analogues.
Hematology Cell Therapy, 38:s67-s74, 1996.
Keating, M.J., O'Brien, S., McLaughlin, P., Dimopoulos, M., Gandhi, V., Plunkett, W.,
Lerner, S., Kantarjian, H., and Estey, E. Clinical experience with fludarabine in
hemato-oncology. Hematology Cell Therapy, 38:s83-s91, 1996.

24. Plunkett, W., Huang, P. and Gandhi, V. Gemcitabine: Actions and interactions.
Nucleosides Nucleotides, 167:1261-1270, 1997.
25. Gandhi, V., Estey, E., Keating, M. J. and Plunkett, W. Fludarabine potentiates
metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy: An Update. J. Clin. Oncol. Classic Papers & Current Comments, 4:9-18, 1999. 26. Plunkett, W., Kawai, Y., Sandoval, A., O’Brien, S., Keating, M. J. and, Gandhi, V.
Mechanism-based rationales for combination therapies of lymphoid malignancies. Hematologica 84(Suppl. 10):73-77, 1999. 27. Nabhan, C., Krett, N., Gandhi, V., and Rosen, S. Gemcitabine in hematologic
malignancies. Curr. Opinion Oncol., 13:514-521, 2001. 28. Rodriguez, C.O. and Gandhi, V. Nelarabine: A new drug for hematological
malignancies. Haematologica, 86(Suppl. 1-11):43-47, 2001. 29. Gandhi, V. Metabolism and mechanisms of action of bendamustine: Rationales for
combination therapies. Sem. Oncol.,4 (Suppl. 13):4-11, 2002. 30. Cooper, T., Kantarjian, H., Plunkett, W., Gandhi, V. Clofarabine in adult acute
leukemias: Clinical success and pharmacokinetics. Nucleosides, Nucleotides, and Nucleic Acids, 23:339-345, 2004. 31. Faderl, S., Gandhi, V., Keating, M.J., Jeha, S., Plunkett, W. and Kantarjian, H.M. The
role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer, 103:1985-1995, 2005. 32. Gandhi, V. Guest Commentaries: Clofarabine: A viewpoint by Varsha Gandhi.
33. Gandhi, V., Keating, M.J., Bate, G., and Kirkpatrick, P. Nelarabine. Nature Reviews
34. Ravandi, F. and Gandhi, V. New purine nucleoside analogues for T-cell acute
lymphoblastic leukemia (T-ALL) and lymphoma. Expert Opinion on Investigational Drugs, 15:1601-1613, 2006. 35. Mehta, K., Gandhi, V., and Aggarwal, B.B. All pathways to cancer apoptosis meeting
in Thiruvananthapuram (India): Meeting Report. Cell Death and Differentiation 13:2163-2164, 2006. 36. Gandhi, V., and Plunkett, W. Clofarabine and nelarabine: Two new purine nucleoside
analogs. Curr. Opin. Oncol. 18:584-590, 2006. 37. Gandhi, V. Forodesine – Preclinical studies. Hematologica Reports 2:35-37, 2006.
38. Kantarjian, H., Jeha, S., Gandhi, V., Wess, M., and Faderl, S., Clofarabine-Past,
present, and future. Leuk. Lympho., 48:1922-1930, 2007. 39. Gandhi, V. p53 as a predictor for chemotherapy response in CLL cells. Leuk.
40. Gandhi, V. and Balakrishnan, K. Forodesine- A T-cell targeted therapeutic. Sem.
41. Faderl, S., Gandhi, V., and Kantarjian, H.M. potential role of novel nucleoside analogs
in the treatment of acute myeloid leukemia. Curr. Opinion Hematol. 15:101-107, 2008. 42. Stellrecht, C. and Gandhi, V. Met receptor tyrosine kinase as a therapeutic anticancer 43. Gandhi, V. Forodesine. Hematology Meeting Reports 3:70, 2009.
44. Sampath, D. & Gandhi, V. Dialing up a Notch. Leuk. Lympho. 50:158-159, 2009.
45. Stellrecht, C. & Gandhi, V. Myeloma antioxidant status: the good, the bad and the
reactive. Leuk. Lympho. 50:691-693, 2009 c. Editorials: None. d. Other Articles: 1. Gandhi, V. Novel inhibitors of DNA replication. American Society of Hematology:
Educational Program Book, Hematology 463-469, 1999. 2. Stellrecht, C., Chen L.S., and Gandhi, V. Inhibition of oncogene expression by RNA-
directed agents. American Association for Cancer Research: Educational Program Book, 2005. 1. Faderl, S., Gandhi, V., Cortes, J., Wierda, W., O’Brien, S., Keating, M.J., Craig, A.,
Kwari, M., Plunkett, W., Kantarjian, M. Clofarabine is active as a single agent and in combination with ara-C in patients (pts) with relapsed/refractory acute leukemias and high-risk myelodysplastic syndrome (MDS). Proc. Am. So. Clin. Oncol., 22:586, 2003. 2. Cooper, T., Nowak, B., and Gandhi, V. Biochemical modulation of cytarabine
triphosphate by clofarabine. Proc. AACR, 44:119, 2003. 3. Pillai, R.N., Nowak, B., Keating, M.J., and Gandhi, V. Multifaceted actions of 8-
amino-adenosine result in cell death of BCR-ABL positive cells. Proc. AACR, 44:124-125, 2003. 4. Sampath, D., Cortes, J., Du, M., Terry, N., Shi, Z., Andreeff, M., Gandhi, V., and
Plunkett, W. Action of 7-hydroxystaurosporine (UCN-01) in combination with ara-C on S phase checkpoint activation and survival pathways during therapy of AML. Proc. AACR, 44:558, 2003. 5. Sanchez-Vega, B., Rosen, S., and Gandhi, V. Mechanism of glucocorticoid resistance
in multiple myeloma cell line. Proc. AACR, 44:1305, 2003. 6. Faderl S, Gandhi V, Garcia-Manero G, Thomas DA, Cores JE, O’Brien S, Estey E,
Craig A, Weiss J Keating M, Verstovsek S, Giles FJ, Kwari M, Plunkett W, and Kantarjian HM. Clofarabine is active in combination with cytarabine (ara-C) in luekemia and high-risk myelodysplastic syndrome (MDS). Blood, 102:615a, 2003. 7. Thomas DA, Wierda W, Faderl S, O’Brien S, Kornblau S, Koller C, Bantia S, Kiltpatrick M, Bennett JC, Kantarjian H, and Gandhi V. Preliminary activity of
intravenous BCX-1777 in aggressive T-cell malignancies. Blood, 102:251-252b, 2003.
8. Balakrishnan K. Ayres M, Keating MJ and Gandhi V. Bioenergetically compromised
and transcriptionally challenged chronic lymphocytic leukemia cells under apoptosis with halogenated ATP. Proc AACR, 45:477, 2004. 9. Sanchez-Vega B, Rosen ST and Gandhi V. Transcription of glucocorticoid receptor
and resistance in multiple myeloma. Proc AACR, 45:99-100, 2004. 10. Stellrecht CM, Krett N, Rosen S, and Gandhi V. Effect of 8-Chloro-Adenosine on
MET Expression and Downstream Activities in Multiple Myeloma. Proc AACR, 45:476-477, 2004. 11. Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-
Manero G, Koller C, O’Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W and Kantarjian HM. Clofarabine plus cytarabine (ara-C) combination is active in newly ≥ age 50 with acute myeloid leukemia and myelodysplastic 12. Faderl S, Ferrajoli A, Wierda W, Verstovsek S, Ravandi-Kashani F, Garcia-Manero G, Estey E, Thomas DA, Kornblau S, Kwari M, Gandhi V, and Kantarjian HM. Phase I
study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine
(ara-C) in patients with relapsed and primary refractory acute myeloid leukemia,
myelodysplastic syndrome, and myeloid blast phase of chronic myeloid leukemia.
Blood 104:501a, 2004.
13. Ghias, K, Ma C, Gandhi, V, Krett N, and Rosen ST. 8-amino-adenosine induces loss
of phosphorylation of ERK1/2, p38 MAPK, and Akt kinase; Role in induction of apoptosis in multiple myeloma. Blood 104:919a, 2004. 14. Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O’Brien S, Plunkett
W, Garcia-Manero G, Jackson E, Kantarjian H, and Andreeff M. 2 Chlorodeoxyadenosine (2-CdA) and cytarabine (ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome. Blood 104:274b, 2004. 15. Furman RR, Gandhi V, Bennett JC , Bantia S and Kilpatrick JM. Intravenous
forodesine (BCX-1777), a novel purine nucleoside phosphorylase inhibitor, demonstrates clinical activity in Phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 104:750a, 2004. 16. Isola L, Furman RR, Gandhi V, Thomas DA, Bennett JC, Bantia S and Kilpatrick JM.
Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase inhibitor, in Phase I/II trials in patients with advanced T-cell malignancies. Blood 104:208b, 2004. 17. Balakrishnan K, Keating MJ, and Gandhi V. The RNA-directed analog, 8-amino-
adenosine induces cytotoxicity in human CLL cells. Proc AACR, 46:146-147, 2005. 18. Chen LS and Gandhi V. Cordycepin inhibits polyadenylation and induces cell death in
multiple myeloma cells. Proc AACR, 46:148-149, 2005. 19. Bhagat R, Goldsby RE, Bugni JM, Preston BD, and Gandhi V. Gemcitabine induced
20. Lyu M-A, Cheung LH, Marks JW, Hittelman WN, Gandhi V, and Rosenblum MG.
The growth factor toxin construct rGel/BLyS specifically targets tumor cells expressing BAFF-R, TACI, and BCMA. Proc AACR, 46:355-356, 2005. 21. Frey JA, Pederson IM, Reed JC, Ayres M, Krett NL, Rosen ST, and Gandhi V.
Involvement of both intrinsic and extrinsic cell death pathways by 8-amino-adenosine in multiple myeloma. Proc AACR, 46:768-769, 2005. 22. Chen R, Keating MJ, Gandhi V, and Plunkett W. Flavopiridol induces apoptosis in
chronic lymphocytic leukemia (CLL) cells through the transcriptional down-regulation of anti-apoptotic proteins. Proc AACR, 46:769, 2005. 23. Sanchez-Vega B and Gandhi V. Mechanism of regulation of glucocorticoid receptor
gene expression in glucocorticoid resistant multiple myeloma cell line. Proc AACR, 46:952, 2005.
24. Stellrecht CM and Gandhi V. Multiple myeloma cell killing by 8-chloro-adenosine
overcomes the survival mechanisms generated by the receptor tyrosine kinase, MET. Proc AACR, 46:952, 2005. 25. Teakell SM, Nimmanapalli R, Stellrecht CM, and Gandhi V. Effect of 8-chloro- adenosine and cyclophosphamide combination in multiple myeloma cell line. Proc. AACR, 47:123, 2006. 26. Chen LS and Gandhi V. Polyadenylation inhibition by the triphosphates of cladribine,
clofarabine, and fludarabine. Proc. AACR, 47:132, 2006. 27. Stellrecht CM and Gandhi V. Targeting MET in breast cancer with the transcription
inhibitor, 8-chloro-adenosine. Proc. AACR, 47:713, 2006. 28. Phillip C, Stellrecht CM, Tsai C-Y, and Gandhi V. Flavopiridol, a transcription
inhibitor, induces apoptosis in multiple myeloma. Proc. AACR, 47:891, 2006. 29. Frey JA and Gandhi V. Mechanism of cell death by 8-amino-adenosine. Proc. AACR,
30. Balakrishnan K, Nimmanapalli R, Keating MJ, Ravandi F, and Gandhi V. Preclinical
and early clinical study of forodesine hydrochloride (FH) in chronic lymphocytic leukemia (CLL). Proc. AACR, 47:1329-1330, 2006. 31. Faderl S, Gandhi V, O’Brien S. Giles F, Cortes J, Plunkett W, and Kantarjian H.
Clofarabine is active in myelodysplastic syndrome (MDS). Blood 108:7521, 2006. 32. Balakrishnan K, Wierda W, Keating M, and Gandhi V. Molecular mechanisms of
gossypol-induced apoptosis in CLL cells. Proc. AACR, 48:1141-1142, 2007. 33. Phillip C, Nimmanapali R, Stellrecht C, and Gandhi V. Flavopiridol induces apoptosis
in multiple myeloma: Role of MET in cell death. Proc. AACR, 48:348, 2007.
34. Bhagat R, Albertson T, Preston B, and Gandhi V. The role of polymerase proofreading
in DNA damage and cell death. Proc. AACR, 48:265-266, 2007.
35. Chen L, and Gandhi V. Inhibition of mammalian polyadenylation by ATP analogs.

36. Gomez F, Nimmanapalli R, and Gandhi V. Transcription inhibition of heat shock
proteins: A strategy for combination of 17AAG and actinomycin D. Proc. AACR, 48:1354, 2007.
37. Stellrecht C, Arya R, and Gandhi V. Depletion of cyclin E in breast cancer cells by
treatment with the transcription inhibitor, 8-Cl-Ado. Proc. AACR, 48:778-779, 2007.
38. Frey J, and Gandhi V. 8-Amino-adenosine inhibits RNA transcription by decreasing
phosphorylation of the RNA polymerase II C-terminal domain. Proc. AACR, 48:573, 2007. 39. Balakrishnan K, Burger J, Keating M, Wierda W, Gandhi V. AT-101-induced
apoptosis in CLL cells in independent of cell adhesion-mediated drug resistance. American Association for Cancer Research 49:553 (#2345), 2008. 40. Stellrecht CM, Ayres M, Arya R, Gandhi V. Differential effect of the ribonucleoside
analog, 8-chloro-adenosine, in non-transformed mammary epithelial cells versus breast cancer cells. American Association for Cancer Research 49:780 (#3286), 2008. 41. Chen L, Zhang S, Nowak B, Ayres M, Stellrecht CM, Krett N, Rosen S, Gandhi V.
Inhibition of ATP synthase by halogenated adenosine analog. American Association for Cancer Research 49:755 (#3182), 2008. 42. Chen L, Zhang S, Nowak B, Ayres M, Stellrecht CM, Krett N, Rosen S, Gandhi V.
Inhibition of ATP synthase by halogenated adenosine analog. American Association for Cancer Research 49:755 (#3182), 2008. 43. Gomez F, Nimmanapalli R, Gandhi V. Ribonucleoside analogue, 8-Chloro-Adenosine
is synergistic with 17-AAG. American Association for Cancer Research 49:1341 (#5643), 2008. 44. Chen, R, Chubb S, Hoch U, Harwin R, Fox J, Gandhi V, Plunkett W. SNS-032 , a
novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines. American Association for Cancer Research 49:177 (#756), 2008. Parikh, V. and Sehgal, C. B. Structure and function of the endosperm in Cajanus
cajan. In Advances in Plant Reproductive Physiology (ed.) C. P. Malik, pp. 219-221,
1977.
Venketeswaran, S., Nagmani, R. and Gandhi, V. Tissue culture propagation of
selected tree genera for biomass. In Bioenergy 84 (ed.) H. Egneus and A. Ellegard, pp.
47-51, 1985.
Plunkett, W., Gandhi, V., Grunewald, R., Heinemann, V., Estey, E. and Keating, M.
Pharmacologically directed design of AML therapy. In Acute Myelogenous Leukemia:
Progress and Controversies. (ed.) R. P. Gale, pp. 481-492, 1990.
Gandhi, V., Huang, P., Xu, Y-Z., Heinemann, V. and Plunkett, W. Metabolism and
action of 2',2'-difluorodeoxycytidine: Self-potentiation of cytotoxic activity. In Purine
and Pyrimidine Metabolism in Man VII, Part A. (ed.) A. Harkness, G. Elion, and N.
Zollner, Plenum Press, New York, pp. 125-130, 1991.
Gandhi, V., Estey, E., Keating, M. J. and Plunkett, W. Biochemical basis for
combination chemotherapy. In Acute Leukemias III: Pharmacokinetics and
Management of Relapsed and Refractory Disease", Ed. Hiddemann, W., Buchner, T.,
Plunkett, W., Keating, M.J., and Andreeff, M., Springer-Verlag, pp. 258-261, 1992.
Plunkett, W., Gandhi, V., Kantarjian, H., and Keating, M. J. Pharmacologically guided
leukemia therapy. In Acute Leukemias: Pharmacokinetics and Management of
Relapsed and Refractory Disease", Ed. Hiddemann, W., Buchner, T., Plunkett, W.,
Keating, M.J., and Andreeff, M. Springer-Verlag, pp. 253-257, 1992.
Plunkett, W. and Gandhi, V. Cellular metabolism of nucleoside analogues in CLL:
Implication for drug development. In Chronic Lymphocytic Leukemia. Ed. Cheson, B.,
Marcel Dekker, New York, pp 197-220, 1992.
Gandhi, V., Keating, M. J., Estey, E., and Plunkett, W. Modulation of
arabinosylcytosine metabolism by fludarabine: Therapy for acute myelogenous
leukemia. In Acute Leukemias: Prognostic Factors and Treatment Strategies III. Ed.
Hiddemann, W., Buchner, T., and Wormann, B., Springer-Verlag, pp. 135-139, 1993.
Gandhi, V., Estey E., and Plunkett, W. Modulation of arabinosylcytosine metabolism
during leukemia therapy. In Purine and Pyrimidine Metabolism in Man VIII, (ed.) A.
Sahota and M. Taylor, Plenum Press, New York, pp. 119-124, 1995.
Gandhi, V., Du, M., Chapman, A.J., Huang P., Estey, E., Keating, M. J., and Plunkett,
W. Fludarabine and ara-C combination for treatment of adult acute myelogenous
leukemia: Pharmacokinetic and pharmacodynamic effects. In Acute Leukemias V:
Experimental Approaches and Management of Refractory Diseases. Ed. Hiddemann,
W., Buchner, T., and Wormann, B., Springer-Verlag, 25-31, 1996.
Hertel, L.W., Kroin, J.S., Grossman, C.S., Grindey, G.B., Dorr, A.F., Storniolo,
A.M.V., Plunkett, W. Gandhi, V., and Huang P. Synthesis and biological activity of
2’,2’-difluorodeoxycytidine (gemcitabine). In Biomedical Frontiers of Fluorine
Chemistry. Ed. Ojima, I., McCarthy J.R., and Welch, J.T. ACS Symposium Series,
265-278, 1996.
Plunkett, W. and Gandhi, V. Nucleoside analogs: Cellular pharmacology, mechanisms
of action, and strategies for combination therapy. In Nucleoside Analogs in Cancer
Therapy. Ed. Cheson, B., Keating, M.J., and Plunkett, W. Marcel Dekker, New York,
pp 1-36, 1997.
Gandhi, V., Rodriguez, C.O., and Keating, M. J. Cellular metabolism
and T-ALL specificity of arabinosylguanine: A review. In Acute Leukemias VII: Experimental Approaches and Novel Therapies. Ed. Hiddemann, W., Buchner, T., and Wormann, B. Springer-Verlag, 614-619, 1998.
14. Gandhi, V., Estey, E., Seymour, J.F., Sampath, D., Du, M., Ayers, M., Keating, M. J.,
and Plunkett, W. Modulation of ara-C metabolism to improve AML response. In Acute Leukemias VII: Experimental Approaches and Novel Therapies. Ed. Hiddemann, W., Buchner, T., and Wormann, B. Springer-Verlag, 577-583, 1998.
15. Keating, M., Kantarjian, H., Gandhi, V., O’Brien, S., Koller, C., Kornblau, S., Beran,
M., Andreeff, M., Plunkett, W. and Freireich, E. FLAG-Ida, an effective regimen for high risk AML. Acute Leukemias VII: Experimental Approaches and Novel Therapies. Ed. Hiddemann, W., Buchner, T., and Wormann, B. Springer-Verlag, 828-833, 1998.
16. Plunkett, W., Ruiz van Haperen, V.W., Huang, P., and Gandhi, V. Gemcitabine: A
strategy for combination therapy in ovarian cancer. In Ovarian Cancer 5, Ed. Sharp, F., Blackett, T., Berek, J., and Bast, R. ISIS Medical Media, Ltd. Oxford, 185-394, 1998. 17. Gandhi, V. and Plunkett, W. Combination strategies for purine nucleoside analogs, In
The Chronic Lymphocytic Leukemias: Revised and Expanded. Ed. Cheson, B.D. Marcel Dekker, New York, 195-208, 2001. 18. Plunkett, W. and Gandhi, V. Purine and pyrimidine nucleoside analogs. In Cancer
Chemotherapy and Biological Response Modifiers Annual 19. Ed. Giacconi, G., Schilsky, R., and Sondel, P. Elsevier Science Ltd., Oxford, 21- 45, 2001. 19. Faderl, S., Gandhi, V., Kantarjian, H., and Plunkett, W. New nucleoside analogs. In
Cancer Chemotherapy and Biological Response Modifiers Annual 20. Ed. Giacconi, G., Schilsky, R., and Sondel, P. Elsevier Science Ltd., Oxford, 37-58, 2002. 20. Stellrecht, C.M., Krett, N., Ayres, M., Rosen, S., and Gandhi, V. 8-chloro-cAMP
serves as a prodrug for the RNA directed nucleoside analog, 8-chloro-adenosine. Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies. Ed. Hiddemann, W., Buchner, T., Ritter, J., Unterhalt, M., and Haferlach, T. Springer-Verlag, 193-199, 2003. 21. Vega, B.S. and Gandhi, V. Mechanisms of Glucocorticoid Actions and Resistance in
Multiple Myeloma, In Drug Resistance in Malignant Disease. Ed. Teicher B.A. The Humana Press, Inc., New Jersey, 2005. 22. Gandhi, V. and Plunkett W. Clofarabine: Mechanisms of action, pharmacology, and
clinical investigations, In Deoxynucleoside Analogs. Ed. Peters G.D. The Humana Press, Inc., New Jersey, 2006. 23. Stellrecht, C.M. and Gandhi, V. CML: M.D. Anderson experience. In Chronic
Myeloid Leukemia: An Update. Ed. Agarwal, M.B. The Image Productions, Mumbai, India, 2007. g. Books: None h. Letters to Editor: None i. Manuals: None j. Other: 1. Gandhi, V. Combination of fludarabine and arabinosylguanine in CLL: Preclinical data
and rationale for protocol design. In: CLL – The Cutting Edge. Summer 1998. 2. Gandhi, V. Transcription as a target for cancer therapeutics. Proceedings for the
American Association for Cancer Research Education Book :331, 2005.
Editorial & Review Activities:

Editorial Board:
Jan.

Teaching:

Within Current Institution
Director, GSBS Graduate Academic Program in Experimental Therapeutics, starting date Fall 2009 Coordinator, GS04-0213, Mechanisms in Cancer Therapeutics, GSBS, Spring, 3-semester credit hours, 2003-present Coordinator, GS04-0103, Principles of Therapeutics, GSBS, Fall, 3-semester credit hours, 2008-2009 Instructor, GS04-0213, Mechanisms in Cancer Therapeutics, GSBS, 5 lectures, 2000-present Instructor, Medical fellows core curriculum, Medical School, one lecture Instructor, GS04-0063, Cancer Biology I, GSBS, one lecture, 2000-2008 Instructor, GS21-0232, Translational Research in Cancer, GSBS, one lecture, 2005-present Martha Rodriguez Sandoval, Master’s degree, 1999 Carlos O. Rodriguez, D.V.M. Ph.D. degree, 2001 Beatriz Sanchez-Vega, Ph.D. degree, 2004 Carlos O. Rodriguez, D.V.M. 1995-1999, Chairman Martha Rodriguez Sandoval, 1995-1999, Chairman Shailendra Mundhada, M.D., M.S. student, 2000-2002 Christopher G. Danes, Ph. D. student, 2001-2003 Richard Mendez, M. S. Student, 2003-2004 Rina Bhagat, M.S./Ph.D. student, 2003-2006, Chairman Taichun Qin, M.S./Ph.D. student, 2003-2005 Xueyao Fu, M.S./Ph.D. student, 2003-2005 Jennifer Frey, M.S./Ph.D. student, 2004- 2006, Chairman Claudia Miller, M.S./Ph.D. student, 2004-2006 Scott Michael Teakell, M.S. student, 2004-2007, Chairman Jui-Chuan (Akwen) Tseng, M.S. student, 2004-2007 Cornel Phillip, M.S./Ph.D. student, 2005-2007, Chairman Kathleen Jensen, M.S. student, 2005-2007 Leigh Beth Curtis, M.S. student, 2005- 2007 Fabiola Gomez, M.S./Ph.D. student, 2006-2007, Chairman Cheng-Yu (Olivia) Tsai, Ph.D. student, 2005 - 2007 Leigh Beth Curtis, Ph.D. student, 2007 - present Carlos O. Rodriguez, D.V.M. 1999-2001, Chairman Melita Nasca, Ph.D. student, 2000 – 2002 Beatriz Sanchez-Vega, 2003-2004, Chairman Christopher G. Danes, Ph. D. student, 2004-2007 Richard Mendez, M. S. Student, 2004-2005 Diana Medrano, Ph.D. Student, 2005- 2007 Lei Guo, M.S./Ph.D. student, 2006-2008 Rina Bhagat, Ph.D. student, 2006-2009, Chairman Jennifer Frey, Ph.D. student, 2006-2009, Chairman Cornel Phillip, Ph.D. student, 2007-present, Chairman Claudia Miller, Ph.D. student, 2007-2009 Fabiola Gomez, Ph.D. student, 2008-present, Chairman Kari Brewer, Ph.D. student, 2008-present Violeta Hennessey, Ph.D. student, 2008-present Christopher L. Neal, 2000, Ph.D. student Christopher G. Danes, 2003, Ph. D. student, Chairman Mellisa Vinores Olson, 2005, Ph.D. student Diana Medrano, 2005, Ph. D. student, Chairman Taichun Qin, 2005, Ph.D. student, Chairman Brett Ewald, 2006, Ph.D. student, Chairman Yingjun Jiang, 2006, Ph.D. student Claudia Miller, 2007, M.S./Ph.D. student Yasmine Haddad, 2007, Ph.D. student Cheng-Yu (Olivia) Tsai, 2007, Ph.D. student, Chairman Sandra Saldana, 2009, M.S./Ph.D. student Adam Elwi, 2009, Ph.D. student, External Examiner Cross Cancer Institute, Univ. Alberta, Edmonton, Alberta, Canada Sumaiyah Rehman, 2009, Ph.D. student, Chairman Carlos O. Rodriguez, D.V.M., Tutorial, spring 1995 Rina Bhagat, Tutorial, Spring 2003 Scott Michael Teakell, Fall 2004 Cheng-Yu (Olivia) Tsai, Tutorial, Spring 2005 Rathi Pillai, Pre-Med Student, 2002- 2003 MDACC Post-doctoral Fellow/Research Associate: Lisa Chen, Ph.D. 2004-2008 Jennifer Dennison, Ph.D. 2007-present Amal –El Mabhouh, Ph.D. 2009-present Ramadevi Nimmanapalli, Ph.D. 2005-2007 Kumudha Balakrishnan, Ph.D., 2007- present Lisa Chen, Ph.D. 2008-present Christine Stellrecht, Ph.D. 2008-present Amy J. Chapman, Univ. Colorado, Student extern IV, summer 1990 Savitha Nagarajan, Univ. Houston, Student volunteer, 1995 Jaswinder Legha, Rice Univ., Student extern II, summer 1995 Jaswinder Legha, Rice Univ., Student extern III, summer 1996 Mark Norris, Univ. Newfoundland, Student extern IV, summer 1996 David W. Wang, Rice Univ., Student extern III, summer 1997 Ranjana Mitra, Med. School of Dublin, Student extern, summer 1998 Rishi Arya, Texas Tech Univ., Student extern II, summer 2006 Lecturer for undergraduate and graduate students
Conferences and Symposia:

Organization of National or International Conferences/Symposia:
Chairperson, Session "New approaches in treatment of leukemia", at the Modern Trends in
Human Leukemia IX, Neva-Wilsede Meeting III, St. Petersburg, Russia, June 23, 1994.
Third International Symposium on Drug Resistance in Leukemia. Free University, Amsterdam,
The Netherlands, Chair, Session Antifolates” March 5, 1998.
Chairperson, Session "Bench to Bedside", at the 11th International and 9th European Meeting on
Purines and Pyrimidines in Man, Amsterdam, June 10, 2003.
Organizing Committee, 11th International and 9th European Meeting on Purines and
Pyrimidines in Man, Amsterdam, June 2003.
Second Annual Conference: Targeted Therapies for the Treatment of Hematological
Malignancies, Kauai, HI, Chair “Session III”, August 9, 2004.
Member, Educational Program Committee, 96th Annual Meeting of American Association for
Cancer Research, Anaheim, CA, April 2005.
Chair, Educational Session, “Transcription as a Target for Cancer Therapeutics”, 96th Annual
Meeting of American Association for Cancer Research, Anaheim, CA, April 2005.
Chair, Minisymposium, Novel Therapeutics Target from A to Z, 96th Annual Meeting of
American Association for Cancer Research, Anaheim, CA, April 18, 2005.
Organizing Committee, First International Symposium on Translational Research; Apoptosis &
Cancer, Trivandrum, Kerala, India, Dec. 18-22, 2005.
Organizing Committee, International Hematology Update & Symposium on Advances in
Leukemia/Lymphoma, Jaipur, Rajasthan, India, Feb. 10-12, 2006.
Organizing Committee, Second International Symposium on Translational Research; Natural
Drugs & Cancer, Mumbai, India, Dec. 18-22, 2007.
Chair, Gordon research Conference on Nucleosides, Nucleotides, and Oligonucleotides, Salve
Regina University, Newport, RI, July 5-10, 2009.
Organizing Committee, Third International Symposium on Translational Research; Cancer
Therapeutics and Signaling, Bhubaneswar, Orissa, India, Dec. 18-21, 2009.
Invitations to National or International Conferences: International Symposium on Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease, Muenster, Germany, "Biochemical basis for combination therapy", February 24-26, 1991. International Symposium on Acute Leukemias: Prognostic Factors and Treatment Strategies, Muenster, Germany, "Modulation of ara-C for therapy of AML", February 22-25, 1992. Lymphoma, the next questions., Orlando, Florida, "Rationale for combinations", April 2-5, 1992. NCI Phase I meeting on the Biochemical Modulation of Antimetabolites, National Institute of Health, Bethesda, Maryland, "Biochemical modulation of ara-C by fludarabine", October 27-28, 1992. Berlex Laboratories, Representatives' Meeting, Scottsdale, AZ, "Mode of action of fludarabine", February 2, 1993. Leukemia, the next questions., Houston, Texas, "Does fludarabine make ara-C a better drug?", March 24-27, 1993. Third International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Workshop on Intracellular Monitoring of Nucleoside Analog Drugs: A new Frontier for TDM, Philadelphia, PA, "Anticancer therapy", May 25-28, 1993. Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, Rhode Island, "Fludarabine modulates ara-C metabolism", July 6, 1993. International Society of Experimental Hematology, Satellite Symposium, Rotterdam, The Netherlands, "Metabolism and interactions of fludarabine", August 22, 1993. International Symposium on Acute Leukemias: Experimental Approaches and Management of Refractory Disease, Muenster, Germany, "Pharmacologic and molecular analysis of ara-C modulation by fludarabine", February 28-March 2, 1994. Workshop on Gemcitabine, at the NCI-EORTC Meeting Amsterdam, The Netherlands, "Metabolism and actions of difluoropurines", March 15, 1994. Modern Trends in Human Leukemia IX, Neva-Wilsede Meeting III, St. Petersburg, Russia, "Modulation of arabinosylcytosine during therapy of acute myelogenous leukemia", June 23, 1994. International Conference on Acute Leukemias and Lymphomas. National Research Center for Hematology, Suzdal, Moscow, Russia, "Biological and biochemical modulation of arabinosylcytosine during therapy", June 28, 1994. Second International Symposium on Drug Resistance in Leukemia and Lymphoma. Free University, Amsterdam, The Netherlands, "Ara-C modulation by fludarabine: A strategy to overcome resistance to ara-C", March 6, 1995. Meeting on Zidovudine Phosphorylation in Patients: Methods and Clinical Relevance, Cincinnati, OH, "Nucleoside analogs and monitoring in cancer: Historical perspectives and analogy with antiretrovirals", May 20, 1995. Annual Meeting of the German and Austrian Societies of Hematology. Symposium on Fludarabine, Hamburg, Germany, "Fludara: Mechanism of action", Oct. 8, 1995. VIII Annual Meeting of the Asian Pacific Division of the International Society of Hematology. Symposium on Fludarabine, Brisbane, Australia, "Fludarabine: Pharmacokinetics and mechanism of action", Oct. 16, 1995. National Meeting of the Spanish Society of Hematology and Hematotherapy. Symposium on New Developments in the Treatment of Leukemia and Lymphoma, Zaragoza, Spain, "Purine nucleoside analogs: Action and apoptosis" Nov. 3, 1995. National Meeting of the Spanish Society of Hematology and Hematotherapy. Symposium on New Developments in the treatment of Leukemia and Lymphoma, Zaragoza, Spain, "Future of purine nucleoside analogs in Hemato-oncology" Nov. 3, 1995. Hematologists Symposium on Fludara, Lisbon, Portugal, "Fludarabine: Actions and Apoptosis. Jan. 27, 1996. Symposium on Gemcitabine, at the NCI-EORTC Meeting, Amsterdam, The Netherlands, "Cellular pharmacology", March 12, 1996. Third International Conference on Leukemia, the next questions., New Orleans, LA, "Making drugs work better", Oct. 17-19, 1996. XXII Congress of Brazilian Hematology and Hematotherapy, Porto Alegre, Brazil, "Clinical and pharmacological interactions of 2-CdA" Oct. 29, 1996. International Symposium on Acute Leukemias VII: Experimental Approaches and Novel Therapies, Muenster, Germany, "Novel approaches for therapy of leukemias", February 22-26, 1997. Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, Rhode Island, "Pharmacokinetics of arabinosylguanine", June 29, 1997. IV Pediatric Onco-Hematology Meeting, Recife, Brazil, "Nucleoside analogs for treatment of leukemias", July 24, 1997. IV Pediatric Onco-Hematology Meeting, Recife, Brazil, "Chlorodeoxyadenosine mediated biochemical modulation of ara-C during AML therapy", July 25, 1997. Third International Symposium on Drug Resistance in Leukemia and Lymphoma. Free University, Amsterdam, The Netherlands, "Ara-G: A new nucleoside analogue in leukemia”, March 6, 1998. VI Annual Radiation Workshop at Round Top, TX, "Growth factors and nucleoside analogs for treatment of leukemia", May 2, 1998. 4th International Workshop on the Pharmacodynamics of Anticancer Agents at Dunkeld, Scotland, “Prodrug of arabinosylguanine: PK/PD and clinical responses”, Aug. 28, 1998. Hematologic Malignancies…The Next Questions, Chicago, IL, "GW506U78 (a prodrug of arabinosylguanine): cellular pharmacokinetics and clinical responses", Oct. 9, 1998. Hematologic Malignancies…The Next Questions, Chicago, IL, "A challenging case of hematologic malignancy", Oct. 10, 1998. Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, Rhode Island, "New antimetabolites in clinic: Arabinosylguanine", July 04, 1999. 41st Annual Meeting of American Society of Hematology, Educational Session, Molecular Pharmacology of Novel Anti-Cancer Drugs, New Orleans, LO, “Novel inhibitors of DNA replication”, Dec. 4, 1999. Acute Myelogenous Leukemia- State of the Science Workshop, Session: Drug Resistance, Rockville, MD, “Biochemical modulation strategy for nucleoside analog resistance” Feb. 1, 2000. Acute Myelogenous Leukemia- State of the Science Workshop, Session: Drug Resistance, Rockville, MD, “Cell cycle dysregulation strategy for nucleoside analog resistance” Feb. 1, 2000. VIII Annual Radiation Workshop at Round Top, TX, "Gemcitabine: Pharmacokinetics and mechanism of actions", April 15, 2000. 4th Foundations of Clinical Cancer Research Symposium: Triumphs and Challenges in Oncology, Houston, TX, “Strategies for Combination Chemotherapy in Cancer”, March 8, 2001. 92nd Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, New Orleans, LO, “Discussion Leader”, March 24, 2001. 92nd Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, New Orleans, LO, “Participant, Mock Study Section”, March 24, 2001. BioCryst Pharmaceuticals, Inc., “Nelarabine: Pharmacokinetics and clinical responses”, June 5, 2001. ECCO 11 European Cancer Congress, Hematology Forum, Bendamustine in the Treatment of Hematological Malignancies, Lisbon, Portugal, “Pharmacokinetics and future perspectives with Bendamustine” Oct. 21, 2001. International Workshop on New Drugs in Hematologic Malignancies, Bologna, Italy, “Compound GW506U78 (Nelarabine) in chronic lymphocytic leukemia”, Nov. 13, 2001. 93rd Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, “Discussion Leader”, San Francisco, CA, April 6, 2002. International Workshop on New Drugs in Hematologic Malignancies, Lugano, Switzerland, “New Purine Analogs”, June 11, 2002. Leukemia-2002.Towards the Cure, Miami, FL, "Acute Leukemias –Clofarabine", Sep. 19, 2002. Golfers Against Cancer- Annual Meeting, Houston, TX, “Development of Clofarabine”, Sept. 27, 2002. American Society Hematology, Bioenvision European Investigators Meeting, Philadelphia, PA, “Pharmacokinetics and Pharmacodynamics of Clofarabine”, Dec. 6, 2002. 94th Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, “Discussion Leader”, Washington, DC, July 11, 2003. 94th Annual Meeting of American Association for Cancer Research, Education Session, Associate Member Grant Writing Workshop, “Mock Study Section Participant”, Washington, DC, July 11, 2003. 11th International and 9th European Meeting on Purines and Pyrimidines in Man, Amsterdam, “Clofarabine in Acute Leukemias: Clinical Success and Pharmacokinetics”, June 10, 2003. Annual European Hematological Society (EHA) Meeting, Lyon, “Pharmacology of Nucleoside Analogs: Rationale development of clofarabine”, June 12, 2003. Annual European Hematological Society (EHA) Meeting, Lyon, M. D. Anderson Symposium, “New strategies for the treatment of hematologic malignancies”, June 12, 2003. Annual European Hematological Society (EHA) Clofarabine Investigators’ Meeting, Lyon, “Pharmacodynamics of Clofarabine”, June 13, 2003. Gordon Research Conference, Purines, Pyrimidines & Related Substances, Newport, Rhode Island, "ATP Analogs: Cellular Bioenergetics and Transcription", July 3, 2003. First Annual Conference: Targeted Therapies for the Treatment of Hematological Malignancies, Kona, HI, “Deoxyadenosine and its analogs: From deoxycoformycin to clofarabine”, July 18, 2003. ProQuest Investments Scientific Meeting, Princeton, NJ, “Clofarabine in acute leukemias: Relationship between pharmacokinetics, pharmacodynamics, and clinical response”, Sept. 8, 2003. 95th Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, “Discussion Leader”, Orlando, FL, March 26, 2004. 95th Annual Meeting of American Association for Cancer Research, Sunrise Session, Professional Advancement Series on Career Transition, “Mentor”, Orlando, FL, March 30, 2004. NCI and CLL Research Consortium, Bethesda, MD, “Clofarabine: Pharmacokinetic and pharmacodynamics”, April 24, 2004 Second Annual Conference: Targeted Therapies for the Treatment of Hematological Malignancies, Kauai, HI, “DNA versus RNA directed nucleoside analogs”, August 11, 2004. Leukemia-2004.Towards the Cure, Houston, TX, "Cellular pharmacology in the evaluation of emerging new drugs for leukemias", Oct. 8, 2004. ASH, Corporate Symposia, San Diego, CA, "Cellular pharmacology in the evaluation of emerging new drugs for leukemias", Dec. 3, 2004. 6th International Symposium and Expert Workshops on Leukemia and Lymphoma. “Clofarabine in Acute Leukemias: Relationship between pharmacokinetics/dynamics and response to therapy”. March 19, 2005. 96th Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, Anaheim, CA, “Discussion Leader”, April 16, 2005. 96th Annual Meeting of American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, Anaheim, CA, “Participant, Mock Study Section”, April 16, 2005. 96th Annual Meeting of American Association for Cancer Research, Anaheim, CA, Organizer and Chair for Educational Session, “Transcription as a Target for Cancer Therapeutics”, April 16, 2005. 96th Annual Meeting of American Association for Cancer Research, Anaheim, CA, Presenter, in the Educational Session, “Inhibition of Oncogene Expression”, April 16, 2005. 96th Annual Meeting of American Association for Cancer Research, Anaheim, CA, Member, Organizing committee for Scientific Session, “Experimental Therapeutics – Small Molecules”, April 17, 2005. 96th Annual Meeting of American Association for Cancer Research, Anaheim, CA Member, Co-chair for Scientific Session, “Novel Therapeutic Targets from A to Z”, April 18, 2005. Gordon Research Conference, Nucleoside, Nucleotide, and Oligonucleotides, Newport, Rhode Island, Chair of Session, "Small Molecules and Targets", June 29, 2005. Third Annual Conference: Therapeutic Advances in the Treatment of Hematological Malignancies, Santa Monica, CA, “Targeting c-Met in Multiple Myeloma”, August 5, 2005. Eastern Cooperative Oncology Group (ECOG) Meeting, Tampa, FL, “Clofarabine – Drug for Acute Leukemias”, Nov. 20, 2005. International Symposium on Translational Research: Apoptosis & Cancer, Trivandrum, Kerala, India, “Translational Research with a Targeted Cytotoxic”, December 20, 2005. International Hematology Update & Symposium on Advances in Leukemia/Lymphoma, Jaipur, Rajasthan, India, “Novel & Effective Cytotoxic Treatments for Leukemias – A Close Look at the Bench”, Feb. 11, 2006. 9th Annual Grant Writing Workshop at American Association for Cancer Research Meeting, Educational Session, Washington, DC, “Discussion Leader”, April 1, 2006. 9th Annual Grant Writing Workshop at American Association for Cancer Research Meeting, Educational Session, Associate Member Grant Writing Workshop, Washington, DC, “Participant, Mock Study Section”, April 1, 2006. Annual European Hematological Society (EHA) Meeting, Amsterdam, Satellite Symposium, “Using Cellular Pharmacology in the Evaluation of New Agents”, June 15, 2006. The Leukemia and Lymphoma Society, Translational Research Award Symposium, San Diego, CA, "DNA Independent Strategy to Target CLL", Oct. 21, 2006. International Meeting on T-Cell Lymphomas, Bologna, Italy, “Forodesine, Preclinical Studies” Oct. 23, 2006. American Society Hematology, BioCryst Investigators Meeting, Orlando, FL, “Forodesine, Preclinical Studies”, Dec. 7, 2006. 48th Annual Meeting of the American Society of Hematology, Meet The Expert Session, Orlando, FL, “Nucleoside Analogs in Leukemia”, Dec. 10, 2006. 10th Annual Grant Writing Workshop at American Association for Cancer Research meeting, Educational Session, Associate Member Grant Writing Workshop, Anaheim, CA, “Discussion Leader”, April 14, 2007. 10th Annual Grant Writing Workshop at American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, Anaheim, CA, “Participant, Mock Study Section”, April 14, 2007. Ranbaxy International Hematology Symposium on CML, Mumbai, Maharashtra, India, “Novel Treatments for Leukemias – A Close Look at the Bench”, April 28, 2007. XII International Symposium on Acute Leukemias: Satellite Symposium, Munich, Germany, "Nelarabine- Mechanism of action for T-cell diseases", Feb. 17, 2008 11th Annual Grant Writing Workshop at American Association for Cancer Research meeting, Educational Session, Associate Member Grant Writing Workshop, SanDiego, CA, “Discussion Leader”, April 12, 2008. 11th Annual Grant Writing Workshop at American Association for Cancer Research, Educational Session, Associate Member Grant Writing Workshop, SanDiego, CA, “Participant, Mock Study Section”, April 12, 2008. CLL Global Research Foundation Alliance Meeting, Lake Orta, Italy, “Targeting antiapoptotic proteins in CLL”, June 8, 2008. T-Cell Lymphoma Forum, Washington, DC, “Role of nucleoside analogs in PTCL”, September 20, 2008. Leukemia 2008, Houston, TX, “New agents in T-cell disease”, September 26, 2008. Lymphoma and Myeloma 2008, New York, NY, “Chemistry of Nucleoside analogs”, October 17, 2008. The Leukemia and Lymphoma Society, Translational Research Program Progress Review Meeting, New York, NY, "BLyS-Gelonin: A Targeted Therapeutics for CLL", October 26, 2008. Ranbaxy International Hematology Symposium on CLL, Mumbai, Maharashtra, India, “Novel Treatments for CLL”, Jan 29, 2009. 2006…2009 Now we know T-cell Lymphomas Better, Bologna, Italy, “ BCX-1777 – Forodesine”, March 17, 2009. CLL Global Research Foundation Alliance Meeting, Potsdam, Germany, “Targeting antiapoptotic proteins in CLL”, June 9, 2009. 13th International Symposium on Purine and Pyrimidine Metabolism in Man, Skogshem-Wijk, Lindingo, Stockholm, Sweden, “New Antileukemic Nucleoside Analogs”, June 23, 2009. Research Symposium, Southern Illinois University School of Medicine, Springfield, IL, “Targeting Met Receptor Tyrosine Kinase in Multiple Myeloma”, Oct. 17, 2009. Seminar Invitations from Academic Institutions St. Bartholomew's Hospital, London, Great Britain, Department of Medical Oncology, "Combination of fludarabine and ara-C for therapy of acute myelogenous leukemia", February 21, 1991. Karolinska Institute, Stockholm, Sweden, "Potentiation of ara-CTP accumulation by pretreatment with F-ara-A", February 27, 1991. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Hematology Seminar Series, "Fludarabine modulation of ara-C: Bench to bedside", Dec. 5, 1991. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Pediatrics: Section Update Conference, "Pharmacologic rationale for combination therapy", March 9, 1992. University Hospital Nijmegen, Nijmegen, The Netherlands, Department of Internal Medicine, Division of Medicine, "Successful biochemical modulation of arabinosylcytosine in leukemia therapy", March 13, 1992. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Division of Laboratory Medicine Seminar Series, "Fludarabine & ara-C: Mechanistically derived rationale for combination", March 19, 1993. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Section of Immunology and Drug Delivery Seminar Series, "Fludarabine modulation of ara-C: Bench to bedside and back to bench", June 25, 1993. University of Vienna, Vienna, Austria, Institute for Medical Chemistry, "Biochemical and molecular rationales for clinical success of fludarabine and ara-C in AML", Sept. 2, 1993. Medical University of South Carolina, Charleston, SC, Division of Hematology/Oncology Seminar Series, "Fludarabine and ara-C combination: Biochemical and molecular rationale for clinical success", Sept. 17, 1993. University of Cincinnati Medical Center, Cincinnati, OH, Department of Pathology and Lab Medicine, "Pharmacologically directed design of AML therapy: ara-C as a paradigm", Jan. 20, 1994. Rush-Presbyterian-St. Luke's Medical Center, Rush University, Chicago, IL, Leukemia Program, "Pharmacological, clinical, and molecular rationale for combining fludarabine and ara-C for therapy of AML", May 20, 1994. All India Institute of Medical Sciences, New Delhi, India, Institute of Rotary Cancer Hospital, "Biochemical modulation strategy to increase leukemia response", Nov 7, 1994. Tata Memorial Hospital, Parel, Bombay, India, Department of Medical Oncology, "Modulation of ara-C during therapy for patients with AML", Nov 8, 1994. Central Salt and Marine Research Institute, Bhavnagar, India, Indian Red Cross Society, Indian Medical Association, "Research and medicines on leukemia: Combination of fludarabine and ara-C for therapy of AML", Nov 11, 1994. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Pediatrics, Pediatric Research Conference, "Modulation of ara-C: Pharmacological, clinical, and molecular interactions", May 1, 1995. Duke University, Durham, NC, Department of Pediatric Hematology Oncology, Compound 506U Investigators' Meeting, "Cellular metabolism and action on DNA synthesis", Feb. 5, 1996. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Hematology, Hematology Clinical Research Conference, "506U (ara-G): An effective agent for the treatment of T-cell malignancies", April 11, 1996. Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, Department of Pediatrics, Hematology/Oncology Section research meeting, "506U (ara-G): Metabolism, mechanisms of action, and clinical pharmacology", June 7, 1996. St. Jude Children's Research Hospital, Memphis, TN, Department of Hematology/Oncology, "Rationale and pharmacology of combination of cladribine and ara-C", July 24, 1996. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Division of Laboratory Medicine Seminar Series, "Arabinosylguanine: Pharmacokinetics, pharmacodynamics, and correlates with clinical response", January 10, 1997. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Section of Bioimmunotherapy Seminar Series, "Arabinosylguanine: A remarkable agent for T-ALL", March 10, 1997. St. Jude Children's Research Hospital, Memphis, TN, Department of Hematology/Oncology, "Arabinosylguanine (ara-G, Compound GW506U): A highly-effective compound in T-cell acute lymphoblastic leukemia", March 25, 1997. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Clinical Oncology Grand Rounds, "Arabinosylguanine and New Strategies for T-Cell Diseases", May 23, 1997. Department of Clinical Pharmacology, GlaxoWellcome Inc., Res. Triangle Park, NC "GW506U78, a prodrug of arabinosylguanine: pharmacokinetics and clinical responses", June 2, 1998. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Clinical Investigation Seminar series, "Arabinosylguanine: Past, Present, and Future”, July 27, 1998. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Pediatrics, Pediatric Research Conference, "Arabinosylguanine: A new kid on the block", Sept. 28, 1998. University of Illinois at Chicago, Chicago, IL, Cancer Center Fall Seminar Series, "Arabinosylguanine: A new clinically active nucleoside analog", Oct. 12, 1998. Developmental Therapeutics Program, NCI RAID Investigators Meeting on 8-chloro-adenosine, National Institute of Health, Frederick, Maryland, "Metabolic and mechanistic studies on 8-chloro-adenosine- A nucleoside analog", February 24, 1999. Lurie Comprehensive Cancer Center, Northwestern University Chicago Campus, Chicago, IL, "Arabinosylguanine: A new clinically active nucleoside analog", May 28, 1999. University of Texas M.D. Anderson Cancer Center, Houston, Texas, Department of Pediatrics, Clinical/Basic Research Pediatric Rounds, "Arabinosylguanine", Sept. 30, 1999. NCI and Glaxo Wellcome, Inc. Investigators Meeting on compound506U78, National Institute of Health, Bethesda, Maryland, "Cellular pharmacology investigations during phase I (PGAA1001 and PGAA1005) studies", Nov. 3, 1999. NCI and Glaxo Wellcome, Inc. Investigators Meeting on compound506U78, National Institute of Health, Bethesda, Maryland, "GW506U78, alternate day schedule: Cellular pharmacology investigations", Nov. 3, 1999. University of Texas Medical School, Seminar for Medical Students and Fellows, “Mechanism based combination chemotherapy”, Nov. 1, 2000.

Source: http://ww2.uthouston.edu/dotAsset/1822991.pdf

Microsoft word - standard on the human-centred org

The Human-Centred Organisation Background Tomas Berns at Ergolab AB and System Concepts' founder Tom Stewart are the Project Editors for a new International Standard on The Human-Centred Organisation. This high level standard explains to executive board members the values and beliefs that make an organisation human-centred, the significant business benefits and what policies they need to put in pl

Egipto

1. Arquitectura. La La arquitectura egipcia es arquitrabada. Por lo que respecta a la tumba señalar tumba y el templo. su tipología y la evolución de la pirámide desde el modelo escalonado de Zoser, en Sakkara, hasta la Gran Pirámide de Keops, en Gizeh. En cuanto al templo enumerar sus partes y dependencias, y reflejar su evolución desde los edificios al aire libre (Karnak y Luxo

Copyright © 2010-2014 Drugstore Pdf Search